Global Hepatitis Therapeutics Market Segments 2024, Forecast To 2033
5 Mar, 2024
The hepatitis therapeutics market has experienced steady growth, progressing from $18.35 billion in 2023 to $18.89 billion in 2024, reflecting a 3.0% CAGR. The historic period's growth is attributed to vaccine development, antiviral medications, public health initiatives, research funding, and emerging therapies. Expecting steady growth, the market is projected to reach $21.79 billion in 2028 with a 3.6% CAGR. This growth is sustained by continued research and development, global health efforts, patient care shifts, government initiatives, and rising disease awareness, accompanied by trends like patient advocacy and telemedicine in the forecast period.
Global Hepatitis Therapeutics Market Key Driver
The hepatitis therapeutic market is set to expand due to the rise in hepatitis infections globally. Inadequate access to healthcare, unsafe practices, and poor sanitation contribute to the spread of hepatitis infections. The World Health Organization reports cases of acute hepatitis and estimates 350 million individuals worldwide suffering from viral hepatitis B or C, highlighting the market's growth.
Get A Free Sample Of The Global Hepatitis Therapeutics Market ReportGlobal Hepatitis Therapeutics Market Segments
The hepatitis therapeutics market covered in this report is segmented –
1) By Disease Type: Hepatitis A, Hepatitis B, Hepatitis C, Other Disease Types
2) By Drug Class: Oral Antivirals, Immune Modulators
3) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers
By Geography: The regions covered in the anti inflammatory therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions.
North America was the largest region in the hepatitis therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the hepatitis therapeutics market report during the forecast period. The regions covered in the hepatitis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Hepatitis Therapeutics Industry Players
Gilead Sciences Inc.; Bristol-Myers Squibb Co.; AbbVie Inc.; Merck & Co. Inc.; Johnson & Johnson Services Inc.; Cipla Inc.; F Hoffmann-La Roche Ltd.; Biocon Limited; LAURUS Labs Ltd.; Zydus Lifesciences Limited; Hetero Healthcare Limited; Novartis AG; Sanofi SA; GlaxoSmithKline plc; Lupin Ltd.; Teva Pharmaceutical Industries Ltd.; NATCO Pharma Limited; Mylan NV; Pfizer Inc.; AstraZeneca plc; Bayer AG; Boehringer Ingelheim International GmbH; Eli Lilly and Company; Novo Nordisk A/S; Takeda Pharmaceutical Company Limited; Biogen Inc.; Vertex Pharmaceuticals Incorporated; Biocon Biopharmaceuticals Pvt. Ltd.; Zealand Pharma A/S; Zenyaku Kogyo Co. Ltd.; Zosano Pharma Corporation
Get The Full Global Hepatitis Therapeutics Market Report
AIOps Hepatitis Therapeutics Market Overview
Hepatitis is an inflammation of the liver caused by several viruses and non-viruses. The term hepatitis therapeutics describes the drugs that are used to treat all forms of hepatitis. The two drugs used to treat hepatitis are immune modulators and oral antivirals.
Hepatitis Therapeutics Global Market Report 2023 provides data on the global hepatitis therapeutics market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The hepatitis therapeutics market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.